New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
07:45 EDTBRLI, CSU, ISIS, FOLD, ABBV, PRXL, CEMP, ICLR, TSROUBS to hold a conference
2014 Global Healthcare Conference to be held in New York on May 19-21 with webcasted company presentations to begin on May 21 at 8 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
February 25, 2015
16:03 EDTCEMPCempra sees sufficient funding for ongoing operations into 2017
After giving effect to the net proceeds of the January offering, the company's current cash and equivalents are expected to be sufficient to fund ongoing operations into 2017, assuming continued timely receipts under the BARDA contract and receipt of expected milestone payments from Toyama.
16:02 EDTCEMPCempra reports Q4 EPS (46c), consensus (49c)
Subscribe for More Information
08:36 EDTBRLIBio-Reference Labs launches OnkoSight tumor sequencing program
Subscribe for More Information
06:09 EDTICLRICON plc sees FY15 EPS $3.45-$3.60, consensus $3.26
Sees Fy15 revenue $1.61B$1.675B, consensus $1.64B.
06:08 EDTICLRICON plc reports Q4 adjusted EPS 87c, consensus 76c
Subscribe for More Information
February 24, 2015
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
08:33 EDTFOLDArgos Therapeutics hires Joan Winterbottom as Chief Human Resources Officer
Argos Therapeutics (ARGS) announced that Joan Winterbottom will join the company as chief human resources officer. Winterbottom most recently served as senior vice president of human resources at Amicus Therapeutics (FOLD).
February 23, 2015
11:19 EDTABBVEnanta announces JAMA publication of AbbVie VIEKIRA PAK study results
Subscribe for More Information
11:04 EDTABBVAbbVie reports VIEKIRA PAK HPV/HIV co-infection study results published
Subscribe for More Information
07:22 EDTFOLD, ISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
10:33 EDTABBVBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
07:23 EDTABBVAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.
February 19, 2015
16:13 EDTTSROTESARO reports Q4 EPS ($1.33), consensus ($1.03)
Subscribe for More Information
12:13 EDTABBVAbbVie increases quarterly dividend 4% to 51c per share
Subscribe for More Information
February 17, 2015
18:06 EDTABBVPaulson & Co gives quarterly update on stakes
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use